No­var­tis con­fi­dent­ly breaks out mid-stage da­ta on Xo­lair com­peti­tor

Late last year, No­var­tis in­di­cat­ed its ex­per­i­men­tal ther­a­py lige­lizum­ab was Phase III ready af­ter it out­per­formed Xo­lair — the com­pa­ny’s Roche-part­nered chron­ic spon­ta­neous ur­ticaria ther­a­py …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER